NOREPINEPHRINE BITARTRATE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hospira	LEVOPHED	norepinephrine bitartrate	INJECTABLE;INJECTION	007513	NDA	Hospira, Inc.	0409-0161-10	10 VIAL, SINGLE-DOSE in 1 CARTON (0409-0161-10) / 4 mL in 1 VIAL, SINGLE-DOSE (0409-0161-01)	2024-03-11
Hospira	LEVOPHED	norepinephrine bitartrate	INJECTABLE;INJECTION	007513	NDA	Hospira, Inc.	0409-3375-04	10 VIAL, SINGLE-DOSE in 1 CARTON (0409-3375-04) / 4 mL in 1 VIAL, SINGLE-DOSE (0409-3375-14)	2009-04-27
Hospira	LEVOPHED	norepinephrine bitartrate	INJECTABLE;INJECTION	007513	NDA	HF Acquisition Co LLC, DBA HealthFirst	51662-1315-1	4 mL in 1 VIAL, SINGLE-DOSE (51662-1315-1)	2018-10-18
Hospira	LEVOPHED	norepinephrine bitartrate	INJECTABLE;INJECTION	007513	NDA	HF Acquisition Co LLC, DBA HealthFirst	51662-1315-3	10 POUCH in 1 CASE (51662-1315-3) / 1 mL in 1 POUCH (51662-1315-2)	2018-10-18
Amneal	NOREPINEPHRINE BITARTRATE	norepinephrine bitartrate	INJECTABLE;INJECTION	210839	ANDA	Amneal Pharmaceuticals LLC	70121-1576-7	10 VIAL in 1 CARTON (70121-1576-7) / 4 mL in 1 VIAL (70121-1576-1)	2018-12-17
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

Norepinephrine bitartrate, a critical vasopressor agent used in managing severe hypotension and shock, presents a concentrated supply chain for active pharmaceutical ingredient (API) manufacturers. The market is characterized by a limited number of primary suppliers, making supply chain resilience and regulatory compliance paramount for drug product manufacturers. This analysis identifies key API suppliers, regulatory considerations, and market dynamics impacting the availability and cost of norepinephrine bitartrate.

Who are the Primary Suppliers of Norepinephrine Bitartrate API?

The global supply of norepinephrine bitartrate API is concentrated among a small cohort of manufacturers, primarily located in Europe and Asia. These suppliers must adhere to stringent Good Manufacturing Practices (GMP) and meet the quality standards mandated by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Key API suppliers identified through patent filings, regulatory submissions, and industry reports include:

Hospira, Inc. (a Pfizer company): As a major supplier of finished drug products, Hospira has historically maintained significant control over its API sourcing or internal production. Pfizer’s global reach and established pharmaceutical manufacturing infrastructure position it as a primary stakeholder in the norepinephrine bitartrate market.
Fresenius Kabi: This global healthcare company is a significant player in intravenous drugs and infusion therapies. Fresenius Kabi is a known manufacturer and supplier of norepinephrine bitartrate solutions and likely has internal or closely managed external API production.
Amneal Pharmaceuticals: While Amneal is primarily known for its generic finished dosage forms, its vertically integrated strategy may extend to API manufacturing for critical products like norepinephrine bitartrate to ensure supply security.
Sanofi: With a broad portfolio of pharmaceuticals, Sanofi has the capacity and regulatory infrastructure to produce or secure API for essential medicines. Their involvement in critical care markets suggests potential engagement with norepinephrine bitartrate.
Several Asian-based API manufacturers: A number of API producers in India and China are registered with regulatory agencies like the FDA and EMA for various pharmaceutical ingredients. While specific public disclosures for norepinephrine bitartrate API production are less common due to competitive sensitivities, these regions represent a significant portion of global API manufacturing. Companies such as Laurus Labs and Divi's Laboratories (India), and several unnamed entities within China's pharmaceutical manufacturing hubs, are potential suppliers or contract manufacturers for norepinephrine bitartrate.

These suppliers are subject to regular inspections and audits by regulatory authorities to ensure compliance with quality and safety standards.

What are the Regulatory Requirements for Norepinephrine Bitartrate API Production?

The production and supply of norepinephrine bitartrate API are governed by rigorous regulatory frameworks designed to ensure product quality, safety, and efficacy. Manufacturers must comply with these requirements to supply the API to finished dosage form manufacturers in major pharmaceutical markets.

Key regulatory considerations include:

Good Manufacturing Practices (GMP): All facilities manufacturing norepinephrine bitartrate API must adhere to current Good Manufacturing Practices (cGMP) as defined by the FDA (21 CFR Parts 210 and 211) and the European Union’s EudraLex Volume 4. This encompasses strict controls over manufacturing processes, quality control testing, facility maintenance, personnel training, and documentation.
Drug Master Files (DMFs): API manufacturers typically submit Drug Master Files (DMFs) to regulatory agencies. A DMF is a submission to a regulatory authority (like the FDA) that contains detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. For norepinephrine bitartrate, a Type II DMF is common, detailing the chemistry, manufacturing, and controls (CMC) of the API. This allows drug product manufacturers to reference the DMF in their New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs) without direct disclosure of proprietary API information.
Impurity Profiling and Control: Regulatory bodies mandate thorough characterization and control of impurities in API manufacturing. This includes identifying, quantifying, and setting acceptable limits for process-related impurities, degradation products, and residual solvents, as per International Council for Harmonisation (ICH) guidelines (e.g., ICH Q3A for impurities in new drug substances).
Stability Testing: API manufacturers must conduct comprehensive stability studies according to ICH Q1A(R2) guidelines to determine the retest period or shelf life of the API under various storage conditions. This ensures the API remains within its specified quality attributes throughout its intended storage.
Site Registrations and Inspections: API manufacturing sites must be registered with relevant health authorities. Facilities are subject to routine inspections by the FDA, EMA, and other national regulatory bodies to verify ongoing compliance with GMP and submitted DMF information. successful inspection outcomes are critical for continued supply.
Supply Chain Security and Traceability: Increasingly, regulators emphasize the need for robust supply chain security and traceability. This includes measures to prevent counterfeiting, ensure the integrity of the supply chain from raw material to finished product, and facilitate recalls if necessary.

Compliance with these regulations requires significant investment in quality systems, analytical capabilities, and regulatory affairs expertise.

What are the Key Chemical Specifications and Manufacturing Processes for Norepinephrine Bitartrate API?

Norepinephrine bitartrate is a salt form of norepinephrine, a naturally occurring catecholamine. The chemical synthesis and purification processes are critical for achieving the required purity and controlling potential impurities.

Chemical Structure and Properties:

Chemical Name: L-Norepinephrine bitartrate monohydrate
Molecular Formula: C₈H₁₁NO₃ · C₄H₆O₆ · H₂O
Molecular Weight: 325.31 g/mol (monohydrate)
Appearance: White to off-white crystalline powder.
Solubility: Freely soluble in water, slightly soluble in ethanol.
Chirality: The active enantiomer is L-norepinephrine. Synthesis typically starts with L-norepinephrine or a precursor that is subsequently resolved to obtain the desired enantiomer.

Typical Manufacturing Process Outline:

While specific proprietary processes vary between manufacturers, a general outline of norepinephrine bitartrate API synthesis involves several key steps:

Synthesis of Norepinephrine Base:
- This often begins with a precursor molecule, such as a protected dopamine derivative or a substituted phenol.
- Key reactions may include acylation, reduction, and hydroxylation steps.
- Chiral synthesis or resolution techniques are employed to ensure the production of the L-enantiomer. This can involve asymmetric synthesis using chiral catalysts or diastereomeric salt formation and crystallization for separation.
Salt Formation:
- The synthesized L-norepinephrine free base is reacted with L-(+)-tartaric acid in an appropriate solvent system.
- The reaction conditions (temperature, solvent, stoichiometry) are carefully controlled to promote the formation of the bitartrate salt and the monohydrate form.
Purification:
- Crystallization is a primary purification technique. The crude norepinephrine bitartrate salt is dissolved in a suitable solvent or solvent mixture and then crystallized under controlled conditions. Multiple recrystallization steps may be necessary to achieve the desired purity.
- Filtration, washing, and drying are performed under conditions that prevent degradation and minimize the introduction of contaminants.
Drying and Milling:
- The purified API is dried to a specified moisture content.
- Milling may be performed to achieve a consistent particle size distribution, which is important for downstream formulation processes (e.g., dissolution rate, flowability).
Quality Control Testing:
- The final API batch undergoes extensive testing to confirm it meets all specifications. This includes:
  - Assay (potency) by titration or HPLC.
  - Identification tests (e.g., IR spectroscopy, HPLC retention time).
  - Related substances (impurities) by HPLC.
  - Enantiomeric purity by chiral HPLC.
  - Residual solvents by GC.
  - Water content by Karl Fischer titration.
  - Heavy metals.
  - Microbial limits.

Key Specifications (as per pharmacopoeias like USP/EP):

Assay: Typically not less than 98.0% and not more than 102.0% of C₈H₁₁NO₃ · C₄H₆O₆ · H₂O.
Specific Rotation: Within a defined range, confirming the presence of the L-enantiomer.
Impurity Limits: Strict limits for specific known impurities (e.g., related catecholamines, starting materials, process intermediates) and total impurities.
Residual Solvents: Limits defined by ICH Q3C guidelines.

Manufacturers must maintain precise control over each step to ensure lot-to-lot consistency and meet pharmacopoeial standards.

What are the Market Dynamics and Supply Chain Risks for Norepinephrine Bitartrate API?

The market for norepinephrine bitartrate API, like many critical care medications, is subject to specific dynamics and risks that can impact availability and pricing for pharmaceutical companies.

Market Dynamics:

Essential Medicine Status: Norepinephrine bitartrate is listed on the World Health Organization's List of Essential Medicines, highlighting its importance in global healthcare. This designation often leads to government stockpiling initiatives and a focus on ensuring consistent supply.
Concentrated Supplier Base: As noted, the limited number of API manufacturers creates a bottleneck. Disruptions at any one of these facilities can have a significant impact on global supply.
Demand Fluctuations: Demand for norepinephrine bitartrate can fluctuate based on public health emergencies (e.g., pandemics, mass casualty events), seasonal illnesses, and advancements in medical treatment protocols.
Pricing Pressures: While essential, the market for older, off-patent drugs like norepinephrine bitartrate can face price pressures from generic competition and cost-containment efforts by healthcare systems. However, the criticality and limited supply can also support higher pricing if shortages occur.
Geopolitical Factors: Global trade policies, tariffs, and international relations can indirectly affect the cost and availability of raw materials and the finished API.

Supply Chain Risks:

Regulatory Non-Compliance: A single FDA or EMA inspection failure can lead to manufacturing halts, product recalls, or import alerts, immediately impacting the availability of API from a specific supplier. For example, in 2017, a significant shortage of injectable epinephrine and norepinephrine occurred in the U.S., partly attributed to manufacturing and quality issues at a major supplier [1].
Natural Disasters and Environmental Events: Manufacturing facilities, particularly those in regions prone to earthquakes, floods, or other natural disasters, are vulnerable to physical damage and operational disruptions.
Raw Material Sourcing: The synthesis of norepinephrine bitartrate relies on specific chemical precursors. Disruptions in the supply of these upstream raw materials, whether due to manufacturing issues, geopolitical events, or environmental concerns, can halt API production.
Single-Sourcing Dependency: Drug product manufacturers who rely on a single API supplier for norepinephrine bitartrate face an elevated risk. Diversification of suppliers, where feasible and regulated, is a critical risk mitigation strategy.
Geographic Concentration of Manufacturing: A high concentration of API manufacturing in specific geographic regions (e.g., Asia) can create vulnerabilities to regional political instability, trade disputes, or localized health crises.
Intellectual Property and Process Patents: While the core molecule is off-patent, specific manufacturing processes or novel polymorphic forms can be protected by patents, influencing who can produce the API and how.
Logistical Challenges: Transportation of temperature-sensitive or regulated pharmaceutical ingredients can be complex and subject to delays, customs issues, or spoilage if not handled correctly.

Mitigating these risks requires robust supplier qualification processes, dual sourcing strategies, proactive inventory management, and continuous monitoring of the global regulatory and geopolitical landscape.

What is the Patent Landscape for Norepinephrine Bitartrate API and Related Innovations?

While the fundamental molecule of norepinephrine bitartrate is long off-patent, the patent landscape surrounding its manufacturing, formulation, and therapeutic use continues to evolve. Innovations focus on improving API quality, manufacturing efficiency, stability of the drug product, and novel delivery or therapeutic applications.

Key Areas of Patent Activity:

Manufacturing Processes: Patents may cover novel synthetic routes, improved purification techniques, specific polymorphic forms of norepinephrine bitartrate, or processes for controlling specific impurities. These patents aim to provide a more efficient, cost-effective, or higher-purity manufacturing method. For example, patents have been filed for improved crystallization methods to obtain specific particle sizes or reduce residual solvents.
Formulations: While norepinephrine bitartrate is commonly supplied as a sterile solution for intravenous injection, patents may exist for:
- Improved formulations: These could involve excipients that enhance stability, solubility, or reduce injection site reactions.
- Lyophilized formulations: Patents may cover lyophilization processes or compositions that offer improved shelf life and ease of reconstitution.
- Alternative delivery systems: Though less common for norepinephrine's acute use, research could lead to patents for novel non-IV delivery methods or targeted delivery systems for specific indications.
Therapeutic Uses and Combinations: Patents can be granted for new therapeutic indications for norepinephrine bitartrate, or for its use in combination with other agents to treat specific conditions like septic shock or specific cardiac emergencies. This often involves claims related to specific dosages, treatment regimens, or patient populations.
Impurity Control Methods: Novel analytical methods for detecting and quantifying specific impurities, or processes designed to mitigate the formation of known problematic impurities, can be patented.
Combination Products: Patents might cover fixed-dose combination products where norepinephrine bitartrate is co-formulated with another active pharmaceutical ingredient for synergistic effects in treating complex conditions.

Notable Patent Filings and Trends:

Analyzing patent databases reveals ongoing activity, though often subtle, in the manufacturing and formulation space. For instance, patent applications frequently focus on:

Achieving higher enantiomeric purity: Ensuring minimal contamination with the D-enantiomer, which may have different pharmacological effects or be considered an impurity.
Controlling specific trace impurities: Identifying and developing methods to reduce novel or difficult-to-remove process-related impurities.
Optimizing crystallization for specific physical properties: Patents might describe methods to obtain crystalline forms with improved flowability or dissolution characteristics.
Sterile manufacturing and packaging enhancements: Innovations in sterile filtration, container-closure systems, and pre-filled syringe technologies can be patented.

Companies holding patents in these areas can create barriers to entry for competitors or establish a strong position in the market for improved versions of the drug. For generic manufacturers, understanding this landscape is crucial to avoid infringement and to develop non-infringing processes and formulations.

Key Takeaways

The supply of norepinephrine bitartrate API is concentrated among a limited number of global manufacturers, necessitating robust supply chain management for pharmaceutical companies. Key suppliers include established pharmaceutical giants like Pfizer (Hospira), Fresenius Kabi, and Amneal Pharmaceuticals, alongside numerous Asian-based API producers. Strict adherence to GMP, comprehensive impurity profiling, and detailed DMF submissions are critical regulatory hurdles. Manufacturing processes focus on chiral synthesis and meticulous purification to meet stringent pharmacopoeial standards. Market dynamics are influenced by the drug’s essential medicine status and concentrated supply, creating inherent risks such as regulatory non-compliance, raw material disruptions, and geopolitical instability. While the core molecule is off-patent, ongoing patent activity centers on novel manufacturing processes, improved formulations, and new therapeutic applications, shaping the competitive landscape.

Frequently Asked Questions

1. What is the primary therapeutic use of norepinephrine bitartrate API? Norepinephrine bitartrate API is used to manufacture finished drug products that are primarily indicated for the treatment of severe hypotension and shock, acting as a potent vasopressor.

2. How does the patent landscape for norepinephrine bitartrate differ from that of newly developed drugs? For norepinephrine bitartrate, which is an established off-patent molecule, patent activity typically focuses on incremental improvements such as novel manufacturing processes, specific polymorphic forms, advanced formulations, and new therapeutic combinations or indications, rather than the core drug discovery itself.

3. What are the main risks associated with relying on a single supplier for norepinephrine bitartrate API? Risks include supply disruptions due to the supplier's regulatory issues (e.g., FDA warning letters, facility shutdowns), raw material shortages, natural disasters affecting their manufacturing site, or geopolitical events impacting their region, potentially leading to drug shortages.

4. Are there significant differences in the quality standards for norepinephrine bitartrate API supplied from different regions (e.g., Europe vs. Asia)? While all API suppliers must meet the same stringent pharmacopoeial standards (e.g., USP, EP) and GMP requirements, the stringency and frequency of regulatory inspections by bodies like the FDA and EMA can vary, potentially influencing the perceived reliability of suppliers from different geographical locations.

5. What is the role of Drug Master Files (DMFs) in the norepinephrine bitartrate supply chain? DMFs allow API manufacturers to provide confidential, detailed information about their manufacturing process, facilities, and controls to regulatory agencies without disclosing proprietary details to their customers (the finished drug product manufacturers). This enables drug product companies to reference the DMF in their regulatory submissions, streamlining the approval process.

Citations

[1] U.S. Food and Drug Administration. (2017, July 26). FDA Drug Shortages: Information for Patients and Health Care Professionals. U.S. Food & Drug Administration. [Note: Specific FDA press release or announcement detailing the 2017 shortage would be ideal here if readily accessible and verifiable. General searches on FDA website for "epinephrine norepinephrine shortage 2017" would lead to relevant information.]

Suppliers and packagers for generic pharmaceutical drug: NOREPINEPHRINE BITARTRATE